The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab

Gynecologic Oncology

Volumn 118, Issue 2, 2010, Pages 167-171

  Smerdel, M P ^a,b   Steffensen, K D ^a,b   Waldstrom M ^a   Brandslund, I ^a,b   Jakobsen, A ^a,b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Bevacizumab; Ovarian cancer; Serum VEGF

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CA 125 ANTIGEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL OVARIAN CANCER; FEMALE; HUMAN; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77954243581     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.03.018     Document Type: Article

References (21)

1. J.B. Vermorken, A. Kobierska, B. Chevallier, F. Zanaboni, A. Pawinski, and G.A. Bolis Phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group Ann. Oncol. 11 8 2000 Aug 1035 1040
2. H. Kang, T.J. Kim, Y.Y. Lee, C.H. Choi, J.W. Lee, and D.S. Bae Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study Gynecol. Oncol. 114 2 2009 Aug 210 214
3. P. Sorensen, M. Hoyer, A. Jakobsen, H. Malmstrom, H. Havsteen, and K. Bertelsen phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma Gynecol. Oncol. 81 1 2001 Apr 58 62
4. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat. Med. 1 1 1995 Jan 27 31
5. N. Ferrara Vascular endothelial growth factor as a target for anticancer therapy Oncologist 9 2004 2 10
6. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat. Med. 9 6 2003 Jun 669 676
7. D.J. Hicklin, and L.M. Ellis Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J. Clin. Oncol. 23 5 2005 Feb 10 1011 1027
8. M.A. Cobleigh, V.K. Langmuir, G.W. Sledge, K.D. Miller, L. Haney, and W.F. Novotny A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer Semin. Oncol. 30 5 Suppl 16 2003 Oct 117 124
9. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, and S.L. Topalian A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N. Engl. J. Med. 349 5 2003 Jul 31 427 434
10. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, and W. Heim Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 23 2004 Jun 3 2335 2342
11. L.B. Saltz, S. Clarke, E. az-Rubio, W. Scheithauer, A. Figer, and R. Wong Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J. Clin. Oncol. 26 12 2008 Apr 20 2013 2019
12. S. Hapani, D. Chu, and S. Wu Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis Lancet Oncol. 10 6 2009 Jun 559 568
13. N. Denduluri, S.X. Yang, A.W. Berman, D. Nguyen, D.J. Liewehr, and S.M. Steinberg Circulating biomarkers of bevacizumab activity in patients with breast cancer Cancer. Biol. Ther. 7 1 2008 Jan 15 20
14. B.P. Schneider, M. Wang, M. Radovich, G.W. Sledge, S. Badve, and A. Thor Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J. Clin. Oncol. 26 28 2008 Oct 1 4672 4678
15. M. Stephens, N.J. Smith, and P. Donnelly A new statistical method for haplotype reconstruction from population data Am. J. Hum. Genet. 68 4 2001 Apr 978 989
16. M. Stephens, and P. Scheet Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation Am. J. Hum. Genet. 76 3 2005 Mar 449 462
17. A.A. Garcia, H. Hirte, G. Fleming, D. Yang, D.D. Tsao-Wei, and L. Roman Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J. Clin. Oncol. 26 1 2008 Jan 1 76 82
18. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J. Clin. Oncol. 25 33 2007 Nov 20 5165 5171
19. S.A. Cannistra, U.A. Matulonis, R.T. Penson, J. Hambleton, J. Dupont, and H. Mackey Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J. Clin. Oncol. 25 33 2007 Nov 20 5180 5186
20. S. Hapani, D. Chu, and S. Wu Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis Lancet Oncol. 10 6 2009 Jun 559 568
21. B. Vincenzi, D. Santini, A. Russo, M. Gavasci, F. Battistoni, and G. Dicuonzo Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan Pharmacogenomics 8 4 2007 Apr 319 327